Holen Sie sich die Stockscreener-App
4.11
0.48%
-0.02
Handel nachbörslich:
4.16
0.05
+1.22%
Schlusskurs vom Vortag:
$4.13
Offen:
$4.1
24-Stunden-Volumen:
4.78M
Relative Volume:
1.08
Marktkapitalisierung:
$1.23B
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-7.9038
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
+20.18%
1M Leistung:
+14.48%
6M Leistung:
+5.66%
1J Leistung:
+35.64%
1-Tages-Spanne:
$3.97
$4.18
1-Wochen-Bereich:
$3.34
$4.20
52-Wochen-Spanne:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Vergleichen Sie ABCL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.11 | 1.24B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
How AbCellera Biologics Inc. stock performs in weak economyJuly 2025 WrapUp & Safe Capital Growth Plans - ulpravda.ru
Can AbCellera Biologics Inc. stock hit analyst price targetsMarket Correction Analysis & Maximize Returns With Insights - ulpravda.ru
AbCellera (ABCL) Loses Chief Commercial Officer to Viking Therap - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Trading Up 9.2%Still a Buy? - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025Earnings Beat Highlights & Maximize Gains Professionally - bollywoodhelpline.com
AbCellera settles patent litigation with Bruker over microfluidic device tech - MSN
AbCellera Biologics (NASDAQ:ABCL) Cut to Sell at Wall Street Zen - MarketBeat
Is AbCellera Biologics Inc a good long term investmentMid Cap Growth Trends & These 3 Stocks Could Change Your Portfolio - earlytimes.in
MACD Cross Could Confirm Trend in Sancode Technologies LimitedEmerging Market Stocks & Unlock Patterns Humans Can’t See - earlytimes.in
Update Recap: How AbCellera Biologics Inc stock performs in weak economyExit Point & Real-Time Volume Analysis Alerts - moha.gov.vn
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Upgraded at Wall Street Zen - MarketBeat
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn - Yahoo Finance
AbCellera: Losing Its Undeserved Premium (NASDAQ:ABCL) - Seeking Alpha
AbCellera Appoints Dr. Stephen Quake to Board - MSN
Why AbCellera Biologics Inc. stock is in analyst buy zoneMarket Activity Report & High Accuracy Investment Entry Signals - Улправда
Can AbCellera Biologics Inc. stock beat analyst upgrades2025 Trading Volume Trends & Verified Stock Trade Ideas - Улправда
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - MSN
Will AbCellera Biologics Inc. stock return to pre crisis levels2025 Buyback Activity & Reliable Entry Point Trade Alerts - Улправда
AbCellera Biologics (STU:8QQ) EV-to-OCF : -6.77 (As of Dec. 22, 2025) - GuruFocus
AbCellera Gets $36M In Cell Research Patent Settlement - Law360
Buyout Rumor: How AbCellera Biologics Inc. stock performs in weak economyCEO Change & Weekly High Potential Alerts - DonanımHaber
Published on: 2025-12-19 14:45:34 - Улправда
AbCellera settles patent dispute with Bruker for $36 million upfront By Investing.com - Investing.com India
a2025-12x18brukerlitigat.htm - SEC.gov
AbCellera Secures Global Settlement and Patent License Deal - TipRanks
AbCellera Biologics Inc Settles Patent Litigation with Bruker - TradingView — Track All Markets
AbCellera stock jumps after settlement with Bruker in patent dispute By Investing.com - Investing.com South Africa
AbCellera stock jumps after settlement with Bruker in patent dispute - Investing.com
AbCellera Biologics (NASDAQ:ABCL) Trading 6.7% HigherHere's What Happened - MarketBeat
AbCellera and Bruker Reach Global Settlement of Patent Litigation - PharmiWeb.com
Bruker (BRKR) Agrees to $36M Settlement with AbCellera (ABCL) - GuruFocus
AbCellera (ABCL) Secures $36M Settlement and License Deal with B - GuruFocus
Abcellera and Bruker reach global settlement of patent litigation - marketscreener.com
AbCellera settles patent dispute with Bruker for $36 million upfront - Investing.com
AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement - marketscreener.com
Energy Moves: How interest rate cuts could boost AbCellera Biologics Inc. stockTrade Risk Summary & Accurate Buy Signal Alerts - moha.gov.vn
Norges Bank Makes New $2.16 Million Investment in AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - BioSpace
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):